{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:30:44Z","timestamp":1783186244865,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients. To investigate the efficacy of ETV in Chinese nucleos(t)ide(NA)-experienced CHB patients. Among 89 CHB patients with ETV monotherapy for \u22656 months, 33\/89 (37%) or 56\/89 (73%) were NA-na\u00efve or NA-experienced. During a median follow-up of 5.75 years, all NA-na\u00efve CHB patients achieved VR without genotypic ETV-resistance. However, VR was observed in 50\/56 (~90%) of NA-experienced CHB patients during a median follow-up of 4.75 years. Antiviral efficacy was not reduced in patients with previous lamivudine (LAM) with\/without LAM-resistance (HR 0.465; 95% CI 0.196\u20131.100; <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) (HR 0.472; 95% CI 0.205\u20131.091; <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Patients with a primary treatment failure to adefovir (ADV) had a reduced probability of achieving VR compared to NA-na\u00efve (HR 0.496; 95% CI 0.287\u20130.857; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Previous ADV-experienced patients with a partial VR (HR 1.253; 95% CI 0.429\u20133.665; <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) did not influence antiviral response to ETV. The antiviral efficacy of ETV is not influenced by previous treatment LAM with\/without LAM-resistance. ETV may still be an option in ADV-experienced patients with a partial VR, but not advised in patients with a primary treatment failure to ADV.<\/jats:p>","DOI":"10.1038\/srep28779","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T10:25:20Z","timestamp":1467368720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients"],"prefix":"10.1038","volume":"6","author":[{"given":"Kehui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shisan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"BFsrep28779_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295, 65\u201373, doi: 10.1001\/jama.295.1.65 (2006).","journal-title":"Jama"},{"key":"BFsrep28779_CR2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.cgh.2015.07.007","volume":"13","author":"P Martin","year":"2015","unstructured":"Martin, P. et al. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 13, 2071\u20132087 e2016, doi: 10.1016\/j.cgh.2015.07.007 (2015).","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"key":"BFsrep28779_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/135965350601100614","volume":"11","author":"YF Liaw","year":"2006","unstructured":"Liaw, Y. F. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antiviral therapy 11, 669\u2013679 (2006).","journal-title":"Antiviral therapy"},{"key":"BFsrep28779_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang, T. T. et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52, 886\u2013893, doi: 10.1002\/hep.23785 (2010).","journal-title":"Hepatology"},{"key":"BFsrep28779_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai, C. L. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. The New England journal of medicine 354, 1011\u20131020, doi: 10.1056\/NEJMoa051287 (2006).","journal-title":"The New England journal of medicine"},{"key":"BFsrep28779_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bjid.2012.06.016","volume":"16","author":"SH Zhao","year":"2012","unstructured":"Zhao, S. H. et al. Comparison of entecavir and adefovir for the treatment of chronic hepatitis B. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases 16, 366\u2013372, doi: 10.1016\/j.bjid.2012.06.016 (2012).","journal-title":"The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases"},{"key":"BFsrep28779_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/jac\/dkr495","volume":"67","author":"MC Tsai","year":"2012","unstructured":"Tsai, M. C. et al. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. The Journal of antimicrobial chemotherapy 67, 696\u2013699, doi: 10.1093\/jac\/dkr495 (2012).","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"BFsrep28779_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503\u20131514, doi: 10.1002\/hep.22841 (2009).","journal-title":"Hepatology"},{"key":"BFsrep28779_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7150\/ijms.5472","volume":"10","author":"J Luo","year":"2013","unstructured":"Luo, J. et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. International journal of medical sciences 10, 427\u2013433, doi: 10.7150\/ijms.5472 (2013).","journal-title":"International journal of medical sciences"},{"key":"BFsrep28779_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/hep.22323","volume":"48","author":"M Sherman","year":"2008","unstructured":"Sherman, M. et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical and serology outcomes through 96 weeks. Hepatology 48, 99\u2013108, doi: 10.1002\/hep.22323 (2008).","journal-title":"Hepatology"},{"key":"BFsrep28779_CR11","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","volume":"130","author":"M Sherman","year":"2006","unstructured":"Sherman, M. et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130, 2039\u20132049, doi: 10.1053\/j.gastro.2006.04.007 (2006).","journal-title":"Gastroenterology"},{"key":"BFsrep28779_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jhep.2010.01.012","volume":"52","author":"JG Reijnders","year":"2010","unstructured":"Reijnders, J. G. et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. Journal of hepatology 52, 493\u2013500, doi: 10.1016\/j.jhep.2010.01.012 (2010).","journal-title":"Journal of hepatology"},{"key":"BFsrep28779_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/hep.24406","volume":"54","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk, R. et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 54, 443\u2013451, doi: 10.1002\/hep.24406 (2011).","journal-title":"Hepatology"},{"key":"BFsrep28779_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/IDR.S4188","volume":"4","author":"M Osborn","year":"2011","unstructured":"Osborn, M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infection and drug resistance 4, 55\u201364, doi: 10.2147\/IDR.S4188 (2011).","journal-title":"Infection and drug resistance"},{"key":"BFsrep28779_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51, 422\u2013430, doi: 10.1002\/hep.23327 (2010).","journal-title":"Hepatology"},{"key":"BFsrep28779_CR16","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1111\/jvh.12239","volume":"21","author":"CH Chen","year":"2014","unstructured":"Chen, C. H. et al. Antiviral effect of entecavir in nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. Journal of viral hepatitis 21, e55\u201364, doi: 10.1111\/jvh.12239 (2014).","journal-title":"Journal of viral hepatitis"},{"key":"BFsrep28779_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"57","author":"A Ono","year":"2012","unstructured":"Ono, A. et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. Journal of hepatology 57, 508\u2013514, doi: 10.1016\/j.jhep.2012.04.037 (2012).","journal-title":"Journal of hepatology"},{"key":"BFsrep28779_CR18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","volume":"33","author":"NW Leung","year":"2001","unstructured":"Leung, N. W. et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33, 1527\u20131532, doi: 10.1053\/jhep.2001.25084 (2001).","journal-title":"Hepatology"},{"key":"BFsrep28779_CR19","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok, A. S. et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714\u20131722 (2003).","journal-title":"Gastroenterology"},{"key":"BFsrep28779_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3350\/cmh.2015.21.2.131","volume":"21","author":"JA Hwang","year":"2015","unstructured":"Hwang, J. A. et al. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clinical and molecular hepatology 21, 131\u2013140, doi: 10.3350\/cmh.2015.21.2.131 (2015).","journal-title":"Clinical and molecular hepatology"},{"key":"BFsrep28779_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis, S. J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. The New England journal of medicine 348, 800\u2013807, doi: 10.1056\/NEJMoa021812 (2003).","journal-title":"The New England journal of medicine"},{"key":"BFsrep28779_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"348","author":"P Marcellin","year":"2003","unstructured":"Marcellin, P. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. The New England journal of medicine 348, 808\u2013816, doi: 10.1056\/NEJMoa020681 (2003).","journal-title":"The New England journal of medicine"},{"key":"BFsrep28779_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2893.2008.01053.x","volume":"16","author":"JG Reijnders","year":"2009","unstructured":"Reijnders, J. G. et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. Journal of viral hepatitis 16, 113\u2013120, doi: 10.1111\/j.1365-2893.2008.01053.x (2009).","journal-title":"Journal of viral hepatitis"},{"key":"BFsrep28779_CR24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1365-2036.2011.04785.x","volume":"34","author":"E Sheen","year":"2011","unstructured":"Sheen, E. et al. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. Alimentary pharmacology & therapeutics 34, 767\u2013774, doi: 10.1111\/j.1365-2036.2011.04785.x (2011).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"BFsrep28779_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jgh.12728","volume":"30","author":"NH Nguyen","year":"2015","unstructured":"Nguyen, N. H. et al. Safety and efficacy of entecavir in adefovir-experienced patients. Journal of gastroenterology and hepatology 30, 43\u201350, doi: 10.1111\/jgh.12728 (2015).","journal-title":"Journal of gastroenterology and hepatology"},{"key":"BFsrep28779_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2008.10.033","volume":"50","author":"JG Reijnders","year":"2009","unstructured":"Reijnders, J. G., Pas, S. D., Schutten, M., de Man, R. A. & Janssen, H. L. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. Journal of hepatology 50, 674\u2013683, doi: 10.1016\/j.jhep.2008.10.033 (2009).","journal-title":"Journal of hepatology"},{"key":"BFsrep28779_CR27","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The, L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of hepatology 57, 167\u2013185, doi: 10.1016\/j.jhep.2012.02.010 (2012).","DOI":"10.1016\/j.jhep.2012.02.010"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep28779","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:17:02Z","timestamp":1672849022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep28779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFsrep28779"],"URL":"https:\/\/doi.org\/10.1038\/srep28779","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]},"assertion":[{"value":"22 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28779"}}